Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Fever and cancer: components of diagnosis for optimal management].
Moussaid Y, Bertaux M, Chargari C, Helissey C, Le Moulec S, Errihani H, Vedrine L. Moussaid Y, et al. Among authors: errihani h. Rev Med Interne. 2013 Sep;34(9):545-52. doi: 10.1016/j.revmed.2012.10.368. Epub 2012 Nov 27. Rev Med Interne. 2013. PMID: 23199412 Review. French.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Among authors: errihani h. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.
Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussen H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. Belkacemi Y, et al. Among authors: errihani h. Eur J Cancer. 2020 Aug;135:130-146. doi: 10.1016/j.ejca.2020.05.015. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32580130 Free PMC article. Review.
Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature.
Hachlaf M, Lkhoyaali S, Nadir W, Lemsyeh H, El Ghissassi B, Mrabti H, Boutayeb S, Errihani H. Hachlaf M, et al. Among authors: errihani h. J Med Case Rep. 2024 Aug 8;18(1):374. doi: 10.1186/s13256-024-04706-w. J Med Case Rep. 2024. PMID: 39113087 Free PMC article. Review.
Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR).
Jazieh AR, Bounedjar A, Abdel-Razeq H, Berna Koksoy E, Ansari J, Tfayli AH, Tashkandi EM, Jastaniah WA, Alorabi MO, Darwish AD, Rabea AM, Al Olayan A, Ibnshamsah F, Errihani H, AlKaiyat MO, Hussain F, Alkattan K, Bruinooge SS, Garrett-Mayer E, Tamim H. Jazieh AR, et al. Among authors: errihani h. J Immunother Precis Oncol. 2024 May 2;7(2):82-88. doi: 10.36401/JIPO-23-38. eCollection 2024 May. J Immunother Precis Oncol. 2024. PMID: 38721403 Free PMC article.
297 results